- Home
- AQN vs DNLI Comparison
AQN vs DNLI Comparison
Compare AQN & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AQN | DNLI |
|---|---|---|
| Founded | 1988 | 2013 |
| Country | Canada | United States |
| Employees | 3786 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.7B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | AQN | DNLI |
|---|---|---|
| Price | $5.49 | $25.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | $6.66 | ★ $34.33 |
| AVG Volume (30 Days) | ★ 3.9M | 2.0M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.22% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.87 | N/A |
| Revenue Next Year | $5.02 | $408.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.32 | $12.58 |
| 52 Week High | $7.11 | $26.80 |
Technical Indicators
Market Signals| Indicator | AQN | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 30.79 | 74.24 |
| Support Level | $5.39 | $18.07 |
| Resistance Level | $6.08 | N/A |
| Average True Range (ATR) | 0.14 | 1.15 |
| MACD | -0.04 | 0.24 |
| Stochastic Oscillator | 6.35 | 83.50 |
Price Performance
Historical ComparisonAbout AQN Algonquin Power & Utilities Corp.
Algonquin Power & Utilities Corp is a Canada-based diversified international generation, transmission, and distribution company. The company's operations are organized across two business units: the Regulated Services Group, which owns and operates a portfolio of regulated electric, water distribution, and wastewater collection, and natural gas utility systems and transmission operations in the United States, Canada, Bermuda, and Chile; and the Hydro Group, which consists of hydroelectric-generating facilities located in Canada. It generates the majority of its revenue from the Regulated Services Group segment.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.